Image

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

Testing drug combinations for advanced lung cancer with gene changes.

Recruiting
18 years and older
All
Phase 2
  • Simplified description (AI rewritten)
  • Technical description (Original)

This trial is for patients with advanced non-small cell lung cancer (NSCLC) who have specific gene changes called EGFR and MET. The study tests different combinations of targeted drugs: capmatinib, osimertinib, and/or ramucirumab. These drugs work by blocking proteins that make cancer cells grow and spread. The goal is to see if these combinations can help shrink or control the cancer.

  • The study involves a comparison between two groups: one receiving all three drugs and another receiving capmatinib and osimertinib only.
  • Participants must have measurable disease, meet specific medical criteria, and be willing to undergo regular scans and blood tests.
  • Compensation and travel details are not specified, but participants must agree to participate in blood sample collection for research.

Eligibility requires previously treated lung cancer with certain gene changes. The study has strict medical and safety criteria, including tests for blood counts and organ function. Participants can't have had recent surgeries, specific drugs, or uncontrolled health conditions. Pregnant or breastfeeding individuals are not eligible, and those who can reproduce must agree to use contraception.

Print
Study details
    Recurrent Lung Non-Small Cell Carcinoma
    Stage IV Lung Cancer AJCC v8

NCT05642572

SWOG Cancer Research Network

13 December 2024

Contact a study center
Step 1 Get in touch with the nearest study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

  Other languages supported:

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.